Abstract Cancer cells often upregulate nutrient transporters to fulfill their increased biosynthetic and bioenergetic needs, and to maintain redox homeostasis. One nutrient transporter frequently overexpressed in human cancers is the cystine/glutamate antiporter solute carrier family 7 member 11 (SLC7A11; also known as xCT). SLC7A11 promotes cystine uptake and glutathione biosynthesis, resulting in protection from oxidative stress and ferroptotic cell death. Recent studies have unexpectedly revealed that SLC7A11 also plays critical roles in glutamine metabolism and regulates the glucose and glutamine dependency of cancer cells. This review discusses the roles of SLC7A11 in regulating the antioxidant response and nutrient dependency of cance...
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechani...
Amino acid transporters are membrane transport proteins, most of which are members of the solute car...
open7siThis work was supported by a grant from the National Institute of Health (GM110039) to D.C.C....
Abstract The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import c...
Cystine/glutamate antiporter solute carrier family 7 member 11 (SLC7A11; also known as xCT) plays a ...
SLC7A11 is a cell transmembrane protein composing the light chain of system xc−, transporting extrac...
As noted by Warburg, many cancer cells depend on the consumption of glucose. We performed a genetic ...
Rapidly proliferating cancer cells increase flux through anabolic pathways to build the mass necessa...
Oncogenic mutations in cancer reprogram nutrient metabolism to drive tumor growth and survival under...
AbstractTumor cells have an increased demand for glucose and amino acids to support their rapid grow...
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechani...
Many tumors increase uptake and dependence on glucose, cystine or glutamine. These basic observation...
The Solute Carrier 1A (SLC1A) family comprises a group of membrane proteins that act as dual-functio...
Amino acid transporters (AATs) are membrane-bound transport proteins that mediate transfer of amino ...
The neutral amino acid transporter solute carrier family 1 member 5 (SLC1A5 or ASCT2) is overexpress...
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechani...
Amino acid transporters are membrane transport proteins, most of which are members of the solute car...
open7siThis work was supported by a grant from the National Institute of Health (GM110039) to D.C.C....
Abstract The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import c...
Cystine/glutamate antiporter solute carrier family 7 member 11 (SLC7A11; also known as xCT) plays a ...
SLC7A11 is a cell transmembrane protein composing the light chain of system xc−, transporting extrac...
As noted by Warburg, many cancer cells depend on the consumption of glucose. We performed a genetic ...
Rapidly proliferating cancer cells increase flux through anabolic pathways to build the mass necessa...
Oncogenic mutations in cancer reprogram nutrient metabolism to drive tumor growth and survival under...
AbstractTumor cells have an increased demand for glucose and amino acids to support their rapid grow...
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechani...
Many tumors increase uptake and dependence on glucose, cystine or glutamine. These basic observation...
The Solute Carrier 1A (SLC1A) family comprises a group of membrane proteins that act as dual-functio...
Amino acid transporters (AATs) are membrane-bound transport proteins that mediate transfer of amino ...
The neutral amino acid transporter solute carrier family 1 member 5 (SLC1A5 or ASCT2) is overexpress...
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechani...
Amino acid transporters are membrane transport proteins, most of which are members of the solute car...
open7siThis work was supported by a grant from the National Institute of Health (GM110039) to D.C.C....